IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma

ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (to...

Full description

Autores:
Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo
Tipo de recurso:
Article of investigation
Fecha de publicación:
2021
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/45014
Acceso en línea:
https://hdl.handle.net/10495/45014
Palabra clave:
Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UDEA2_9c9c9bdb495b660f97ef8a046c842f0e
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/45014
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
title IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
spellingShingle IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
title_short IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
title_full IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
title_fullStr IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
title_full_unstemmed IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
title_sort IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
dc.creator.fl_str_mv Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo
dc.contributor.author.none.fl_str_mv Sánchez Caraballo, Jorge Mario
Morales Cárdenas, Edison
Santamaría Salazar, Luis Carlos
Acevedo Vásquez, Ana Milena
Calle Álvarez, Ana María
Olivares Gómez, María Margarita
Gómez García, Carolina
Amaya Ruiz, Emerson Daniel
Cardona Villa, Ricardo
dc.contributor.researchgroup.spa.fl_str_mv Grupo de Alergología Clínica y Experimental (GACE)
dc.subject.decs.none.fl_str_mv Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
topic Asma
Asthma
Biomarcadores
Biomarkers
Eosinófilos
Eosinophils
Inmunoglobulina E
Immunoglobulin E
Terapia Biológica
Biological Therapy
Prueba de Óxido Nítrico Exhalado Fraccionado
Fractional Exhaled Nitric Oxide Testing
https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
dc.subject.meshuri.none.fl_str_mv https://id.nlm.nih.gov/mesh/D001249
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D004804
https://id.nlm.nih.gov/mesh/D007073
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D000089142
description ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (total IgE, sIgE, blood eosinophil, and FeNO) in the framework of severe asthma and assessed its ability to help us to choose the best biological therapy for each patient. Different scenarios (sensitivity analysis) were evaluated according to the biomarkers proposed for each biological therapy in 72 patients with type-2 severe asthma. Between 54.1% and 68% of patients could receive at least 2 different biological therapies and 34.7%-40.2% could receive any of the 3 types of therapies (anti-IgE, anti-eosinophil, anti-IL4). Biomarkers help to identify type-2 severe asthma but total IgE, sIgE, blood eosinophil, and FeNO are not enough to select 1 specific therapy. With the increasing arrival of new biological therapies, it is necessary to identify new biomarkers that allow us to improve our selection criteria for the best therapy for each patient or to construct a prediction rule.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021
dc.date.accessioned.none.fl_str_mv 2025-02-19T16:30:57Z
dc.date.available.none.fl_str_mv 2025-02-19T16:30:57Z
dc.type.spa.fl_str_mv Artículo de investigación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520.
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/45014
dc.identifier.doi.none.fl_str_mv 10.1016/j.waojou.2021.100520
dc.identifier.eissn.none.fl_str_mv 1939-4551
identifier_str_mv Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520.
10.1016/j.waojou.2021.100520
1939-4551
url https://hdl.handle.net/10495/45014
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv World. Allergy. Organ. J.
dc.relation.citationendpage.spa.fl_str_mv 5
dc.relation.citationissue.spa.fl_str_mv 3
dc.relation.citationstartpage.spa.fl_str_mv 1
dc.relation.citationvolume.spa.fl_str_mv 14
dc.relation.ispartofjournal.spa.fl_str_mv World Allergy Organization Journal
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
https://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 5 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.publisher.place.spa.fl_str_mv Atlanta, Estados Unidos
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstreams/03b57465-d379-42f9-a23d-6387623a45ae/download
https://bibliotecadigital.udea.edu.co/bitstreams/b8152a51-2dd2-49cc-b097-a4896bd31d68/download
https://bibliotecadigital.udea.edu.co/bitstreams/17139bd7-b359-48a5-9725-8e0899cbcf58/download
https://bibliotecadigital.udea.edu.co/bitstreams/c29834f1-eaa2-433e-b343-b34b795e064e/download
https://bibliotecadigital.udea.edu.co/bitstreams/cc7d3cdb-bdc7-44ac-8614-d19261b0bbfc/download
bitstream.checksum.fl_str_mv cec7f94b3919e7d00bc0e9fdcfef8d94
b88b088d9957e670ce3b3fbe2eedbc13
8a4605be74aa9ea9d79846c1fba20a33
8012856b44a7c46ec255c7a136484cc6
e7379115c53639ea234c445a9f0d8715
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional de la Universidad de Antioquia
repository.mail.fl_str_mv aplicacionbibliotecadigitalbiblioteca@udea.edu.co
_version_ 1851052481530822656
spelling Sánchez Caraballo, Jorge MarioMorales Cárdenas, EdisonSantamaría Salazar, Luis CarlosAcevedo Vásquez, Ana MilenaCalle Álvarez, Ana MaríaOlivares Gómez, María MargaritaGómez García, CarolinaAmaya Ruiz, Emerson DanielCardona Villa, RicardoGrupo de Alergología Clínica y Experimental (GACE)2025-02-19T16:30:57Z2025-02-19T16:30:57Z2021Sánchez J, Morales E, Santamaria LC, Acevedo AM, Calle A, Olivares M, Gómez C, Amaya D, Cardona R. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021 Mar 5;14(3):100520. doi: 10.1016/j.waojou.2021.100520.https://hdl.handle.net/10495/4501410.1016/j.waojou.2021.1005201939-4551ABSTRACT: Type-2 inflammation is the most frequent endophenotype of asthma. Different biomarkers have been proposed to identify this inflammation because highly effective therapies have improved type-2 severe asthma control. We investigated the frequency of some biomarkers of type-2 inflammation (total IgE, sIgE, blood eosinophil, and FeNO) in the framework of severe asthma and assessed its ability to help us to choose the best biological therapy for each patient. Different scenarios (sensitivity analysis) were evaluated according to the biomarkers proposed for each biological therapy in 72 patients with type-2 severe asthma. Between 54.1% and 68% of patients could receive at least 2 different biological therapies and 34.7%-40.2% could receive any of the 3 types of therapies (anti-IgE, anti-eosinophil, anti-IL4). Biomarkers help to identify type-2 severe asthma but total IgE, sIgE, blood eosinophil, and FeNO are not enough to select 1 specific therapy. With the increasing arrival of new biological therapies, it is necessary to identify new biomarkers that allow us to improve our selection criteria for the best therapy for each patient or to construct a prediction rule.COL00595675 páginasapplication/pdfengElsevierAtlanta, Estados Unidoshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthmaArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAsmaAsthmaBiomarcadoresBiomarkersEosinófilosEosinophilsInmunoglobulina EImmunoglobulin ETerapia BiológicaBiological TherapyPrueba de Óxido Nítrico Exhalado FraccionadoFractional Exhaled Nitric Oxide Testinghttps://id.nlm.nih.gov/mesh/D001249https://id.nlm.nih.gov/mesh/D015415https://id.nlm.nih.gov/mesh/D004804https://id.nlm.nih.gov/mesh/D007073https://id.nlm.nih.gov/mesh/D001691https://id.nlm.nih.gov/mesh/D000089142World. Allergy. Organ. J.53114World Allergy Organization JournalPublicationORIGINALSanchezJorge_2021_IgE_Blood_Eosinophils.pdfSanchezJorge_2021_IgE_Blood_Eosinophils.pdfArtículo de investigaciónapplication/pdf371144https://bibliotecadigital.udea.edu.co/bitstreams/03b57465-d379-42f9-a23d-6387623a45ae/downloadcec7f94b3919e7d00bc0e9fdcfef8d94MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/b8152a51-2dd2-49cc-b097-a4896bd31d68/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/17139bd7-b359-48a5-9725-8e0899cbcf58/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.txtSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.txtExtracted texttext/plain16305https://bibliotecadigital.udea.edu.co/bitstreams/c29834f1-eaa2-433e-b343-b34b795e064e/download8012856b44a7c46ec255c7a136484cc6MD54falseAnonymousREADTHUMBNAILSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.jpgSanchezJorge_2021_IgE_Blood_Eosinophils.pdf.jpgGenerated Thumbnailimage/jpeg17164https://bibliotecadigital.udea.edu.co/bitstreams/cc7d3cdb-bdc7-44ac-8614-d19261b0bbfc/downloade7379115c53639ea234c445a9f0d8715MD55falseAnonymousREAD10495/45014oai:bibliotecadigital.udea.edu.co:10495/450142025-03-26 23:02:21.155http://creativecommons.org/licenses/by-nc-nd/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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